Samira Ait Abdellah, Véronique Raverot, Caroline Gal, Isabelle Guinobert, Valérie Bardot, Claude Blondeau, Bruno Claustrat
{"title":"健康男性志愿者口服缓释片和即刻舌下喷雾剂后褪黑素的生物利用度。","authors":"Samira Ait Abdellah, Véronique Raverot, Caroline Gal, Isabelle Guinobert, Valérie Bardot, Claude Blondeau, Bruno Claustrat","doi":"10.1007/s40268-023-00431-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The benefit of exogenous melatonin is based on its bioavailability, which depends on the galenic form, the route of administration, the dosage, and the individual absorption and rate of hepatic metabolism.</p><p><strong>Objective: </strong>The objective of this study is to investigate the bioavailability of melatonin after administration of an oral prolonged-release tablet (PR form) and an immediate-release sublingual spray (IR form). The main metabolite of melatonin, 6-sulfatoxymelatonin (6-SMT), was also measured, which has not been done in previous studies. Its determination is important as an index of the hepatic transformation of melatonin.</p><p><strong>Methods: </strong>In this single-center, open-label, randomized, crossover study, 14 healthy male volunteers received one tablet of the PR form (1.9 mg melatonin) or two sprays of the IR form (1 mg melatonin) during two visits separated by a washout period. Blood samples were collected over 7 and 9 h for the IR and PR form, respectively, to determine the main pharmacokinetic parameters.</p><p><strong>Results: </strong>The observed kinetics were consistent with those expected for immediate and prolonged-release forms. Pulverization of the spray resulted in an early, high plasma melatonin peak (C<sub>max</sub>: 2332 ± 950 pg/mL; T<sub>max</sub>: 23.3 ± 6.5 min), whereas tablet intake produced a lower peak (C<sub>max</sub>: 1151 ± 565 pg/mL; T<sub>max</sub>: 64.2 ± 44.2 min; p < 0.001 for comparison of C<sub>max</sub> and T<sub>max</sub>) followed by a plasma melatonin plateau and a more prolonged decay over time. Plasma melatonin/6-SMT AUC<sub>0-540/420</sub> ratio was 0.09 for the PR form and 0.16 for the IR form. Both galenic forms were well tolerated.</p><p><strong>Conclusions: </strong>The results suggest that the galenic forms containing melatonin assessed in this study are suitable for the treatment of certain sleep disorders such as sleep onset delay and transient nocturnal awakenings for the IR form and insomnia for the PR form.</p><p><strong>Trial registry: </strong>Registration number: NCT04574141.</p>","PeriodicalId":49258,"journal":{"name":"Drugs in Research & Development","volume":"23 3","pages":"257-265"},"PeriodicalIF":2.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/83/40268_2023_Article_431.PMC10439092.pdf","citationCount":"0","resultStr":"{\"title\":\"Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers.\",\"authors\":\"Samira Ait Abdellah, Véronique Raverot, Caroline Gal, Isabelle Guinobert, Valérie Bardot, Claude Blondeau, Bruno Claustrat\",\"doi\":\"10.1007/s40268-023-00431-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The benefit of exogenous melatonin is based on its bioavailability, which depends on the galenic form, the route of administration, the dosage, and the individual absorption and rate of hepatic metabolism.</p><p><strong>Objective: </strong>The objective of this study is to investigate the bioavailability of melatonin after administration of an oral prolonged-release tablet (PR form) and an immediate-release sublingual spray (IR form). The main metabolite of melatonin, 6-sulfatoxymelatonin (6-SMT), was also measured, which has not been done in previous studies. Its determination is important as an index of the hepatic transformation of melatonin.</p><p><strong>Methods: </strong>In this single-center, open-label, randomized, crossover study, 14 healthy male volunteers received one tablet of the PR form (1.9 mg melatonin) or two sprays of the IR form (1 mg melatonin) during two visits separated by a washout period. Blood samples were collected over 7 and 9 h for the IR and PR form, respectively, to determine the main pharmacokinetic parameters.</p><p><strong>Results: </strong>The observed kinetics were consistent with those expected for immediate and prolonged-release forms. Pulverization of the spray resulted in an early, high plasma melatonin peak (C<sub>max</sub>: 2332 ± 950 pg/mL; T<sub>max</sub>: 23.3 ± 6.5 min), whereas tablet intake produced a lower peak (C<sub>max</sub>: 1151 ± 565 pg/mL; T<sub>max</sub>: 64.2 ± 44.2 min; p < 0.001 for comparison of C<sub>max</sub> and T<sub>max</sub>) followed by a plasma melatonin plateau and a more prolonged decay over time. Plasma melatonin/6-SMT AUC<sub>0-540/420</sub> ratio was 0.09 for the PR form and 0.16 for the IR form. Both galenic forms were well tolerated.</p><p><strong>Conclusions: </strong>The results suggest that the galenic forms containing melatonin assessed in this study are suitable for the treatment of certain sleep disorders such as sleep onset delay and transient nocturnal awakenings for the IR form and insomnia for the PR form.</p><p><strong>Trial registry: </strong>Registration number: NCT04574141.</p>\",\"PeriodicalId\":49258,\"journal\":{\"name\":\"Drugs in Research & Development\",\"volume\":\"23 3\",\"pages\":\"257-265\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/83/40268_2023_Article_431.PMC10439092.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Research & Development\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40268-023-00431-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Research & Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40268-023-00431-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers.
Background: The benefit of exogenous melatonin is based on its bioavailability, which depends on the galenic form, the route of administration, the dosage, and the individual absorption and rate of hepatic metabolism.
Objective: The objective of this study is to investigate the bioavailability of melatonin after administration of an oral prolonged-release tablet (PR form) and an immediate-release sublingual spray (IR form). The main metabolite of melatonin, 6-sulfatoxymelatonin (6-SMT), was also measured, which has not been done in previous studies. Its determination is important as an index of the hepatic transformation of melatonin.
Methods: In this single-center, open-label, randomized, crossover study, 14 healthy male volunteers received one tablet of the PR form (1.9 mg melatonin) or two sprays of the IR form (1 mg melatonin) during two visits separated by a washout period. Blood samples were collected over 7 and 9 h for the IR and PR form, respectively, to determine the main pharmacokinetic parameters.
Results: The observed kinetics were consistent with those expected for immediate and prolonged-release forms. Pulverization of the spray resulted in an early, high plasma melatonin peak (Cmax: 2332 ± 950 pg/mL; Tmax: 23.3 ± 6.5 min), whereas tablet intake produced a lower peak (Cmax: 1151 ± 565 pg/mL; Tmax: 64.2 ± 44.2 min; p < 0.001 for comparison of Cmax and Tmax) followed by a plasma melatonin plateau and a more prolonged decay over time. Plasma melatonin/6-SMT AUC0-540/420 ratio was 0.09 for the PR form and 0.16 for the IR form. Both galenic forms were well tolerated.
Conclusions: The results suggest that the galenic forms containing melatonin assessed in this study are suitable for the treatment of certain sleep disorders such as sleep onset delay and transient nocturnal awakenings for the IR form and insomnia for the PR form.
期刊介绍：
Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy.
The Journal includes:
Clinical research on new and established drugs;
Preclinical research of direct relevance to clinical drug development;
Short communications and case study reports that meet the above criteria will also be considered;
Reviews may also be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
